Novartis has entered an agreement to acquire Endocyte for approximately $2.1bn.
The transaction is expected to be completed in the first half of 2019. It includes the acquisition of all outstanding shares of Endocyte for $24 a share.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition will also add early clinical development candidates to Novartis’s radioligand therapy (RLT) platform, including Endocyte’s late-stage drug candidate 177Lu-PSMA-617 for the treatment of prostate cancer.
Endocyte will be combined with a subsidiary of Novartis upon completion of the acquisition.
Based in Switzerland, Novartis is a multi-national pharmaceutical company, while Endocyte is a biopharmaceutical company based in the US.
Takeda has received approval from the Japanese Trade Fair Commission to proceed with an acquisition of Shire for a total consideration of $62bn.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHaving already received clearance from the US, Brazil and Chinese regulators, the transaction now awaits approval from shareholders of both Takeda and the Japanese Fair Commission, as well as the EU’s antitrust regulators.
The acquisition will enable Takeda to expand its global footprint and develop improved rare disease and plasma-based therapies.
Takeda is a biopharmaceutical company based in Japan, while Shire is a speciality biopharmaceutical company based in Ireland.
Dechra Pharmaceuticals has acquired Brazilian Vencofarma (Venco) for R$185m ($43.42m).
The acquisition will enable Dechra to expand its business in the Brazilian and South American markets.
Based in the UK, Dechra is a manufacturer of specialist veterinary pharmaceuticals, while Venco is a vaccines and animal food products maker based in Brazil.
FSD Pharma has entered a binding letter of intent (LoI) to acquire Therapix Biosciences for $48m.
Under the agreement, shareholders of Therapix Biosciences will receive approximately 130 million class B subordinate shares of FSD Pharma. The transaction is expected to be completed by Q1 2019, subject to shareholder and regulatory approvals.
Based in Canada, FSD Pharma is a licensed producer of marijuana for medical purposes, while Therapix Biosciences is an Israel-based speciality pharmaceutical company developing cannabinoid-based treatments for central nervous system (CNS) disorders.
The acquisition will enable FSD Pharma to enter the medical cannabis market and develop cannabinoid-based treatments.
